Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines

BMB Reports

Volumn 48, Issue 10, 2015, Pages 565-570

  Choi, Song Hee ^a   Park, Byoung Kwon ^a   Lee, Keun Wook ^a   Chang, Jun ^b   Lee, Younghee ^c   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Apoptosis; Cell growth; Hepatocellular carcinoma; Oncolytic effect; RSV

Indexed keywords

ONCOLYTIC VIRUS;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH; DRUG EFFECTS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LIVER NEOPLASMS; METABOLISM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; VIROLOGY;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84946229565     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2015.48.10.268     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108
2. Forver A, Llivet JM and Bruix (2012) Hepatocellular carcinoma. Lancet 379, 1245-1255
3. El-Serag HB and Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576
4. Hoofnagle JH (2004) Hepatocellular carcinoma: summary and recommendations. Gastroenterology 127, S319-S323
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45, 529-538
6. Douek M and Taylor I (2003) Good practice and quality assurance in surgical oncology. Lancet Oncol 4, 626-630
7. Llovet JM, Burroughs A and Bruix J (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917
8. Avila MA, Berasain C, Sangro B and Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25, 3866-3884
9. Woller N, Gürlevik E, Ureche CI, Schumacher A and Kühnel F (2014) Oncolytic viruses as anticancer vaccines. Front Oncol 4, 188
10. Russell SJ, Peng KW and Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30, 658-670
11. Liu TC, Hwang T, Park BH, Bell J and Kirn DH (2008) The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16, 1637-1642
12. Kim JH, Oh JY, Park BH et al (2006) Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther 14, 361-370
13. Heo J, Breitbach CJ, Moon A et al (2011) Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 19, 1170-1179
14. Heo J, Reid T, Ruo L et al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329-336
15. Chang J (2011) Current progress on development of respiratory syncytial virus vaccine. BMB Rep 44, 232-237
16. Atreya PL and Kulkarni S (1999) Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261, 227-241
17. Tregoning JS and Schwarze J (2010) Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23, 74-98
18. Falsey AR and Walsh EE (2000) Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13, 371-384
19. Echchgadda I, Kota S, DeLa Cruz I et al (2009) Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther 16, 923-935
20. Echchgadda I, Chang TH, Sabbah A et al (2011) Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer 11, 43
21. Salimi V, Tavakoli-Yaraki M, Mahmoodi M et al (2013) The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. Iran Red Crescent Med J 15, 62-67
22. Kelly E and Russell SJ (2007) History of Oncolytic Viruses: Genesis to Genetic Engineering. Mol Ther 15, 651-659
23. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7, 781-787
24. Bell JC (2007) Oncolytic viruses: what's next? Curr Cancer Drug Targets 7, 127-131
25. Stanford MM and McFadden G (2007) Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7, 1415-1425
26. Mohr I (2005) To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24, 7697-7709
27. Everts B and van der Poel HG (2005) Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12, 141-161
28. Parato KA, Senger D, Forsyth PA and Bell JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5, 965-976
29. Kim HR, Heo YM, Jeong KI et al (2012) FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep 45, 287-292
30. Youn JK, Kim DW, Kim ST et al (2014) PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model. BMB Rep 47, 569-574
31. Kim S and Chang J (2012) Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease. Immune Netw 12, 8-17
32. Lee YD, Cui MN, Yoon HH, Kim HY, Oh IH and Lee JH (2014) Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA, through NF-kB mediated activation of MMP-9. BMB Rep 47, 262-267
33. Kim DS, Sohn EJ, Kim DW et al (2012) PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression. BMB Rep 45, 532-537